Anti-CD19 CAR T cell therapy for refractory #SLE published in Nature Medicine. 5 pts (22yrs) w/ refractory dz, active SLE (SLEDAI=16). Autologous pt T cells transduced to CD19 CAR Tcells, and lead to remission in 5/5 w/in 3 mos & maintained median 8 mos https://t.co/0epnffCNEN https://t.co/IMRzhOzgei

• https://go.nature.com/3LgIfsA

Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-controlled study Met primary endpoint SRI response across all doses No death, MACE, VTE, systemic infections @RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee

Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE manifestations, specific serologic and proteomic profile. Argues for Sm+ SLE being a specific subset (or even a "different" disease?) @RheumNow #EULAR2022 POS0774 https://t.co/a5dToAuao9

Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/u0UUWKal7n https://t.co/aYFf7Lpx1L

• EULAR Abstract Archive

#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP